Genmab is continuing to build up its pipeline of wholly owned late-stage cancer assets, this time paying $8 billion for Netherlands-based Merus and its bispecific antibody. Analysts praised the ...
Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only covalent Werner helicase (WRN) inhibitor to have made it into the clinic. Vividion and Roche have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback